Complete and partial renal response to voclosporin in difficult-to-treat patients with lupus nephritis: data from the VoRLiSS (Voclosporin in Real Life Setting Study). (EULAR 2026) - Mar 18, 2026 - Abstract #POS0700; B.1128; K195; Pres time: Jun 4, 2026; 09:30 AM - 10:30 AM; Location: Poster View; "CRR was defined by all of the following: 24-hour proteinuria 60 ml/min/1.73 m² with no decrease greater than 20% from baseline, no need for rescue therapies for LN, and daily prednisone dose ≤5 mg...Among previous conventional synthetic DMARDs (csDMARDs), mycophenolate mofetil was the most commonly used (90.9%), followed by cyclophosphamide (74%), whereas Belimumab and hydroxychloroquine were used in 53.2% and 88.3% of cases, respectively...Notably, renal outcomes were comparable between D2T and non- D2T patients, suggesting that voclosporin may be effective even in this challenging population. These promising results need to be confirmed in a larger population with longer follow-up."
Clinical • Cardiovascular • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pulmonary Arterial Hypertension
|
|
Aurora Di Gregorio1; Marta Calatroni2, 3; Marco Allinovi4; Alessandra Bortoluzzi5, 6; Giorgio Buscetta 7; Rossella De Angelis8; Ginevra De Marchi9; Roberto Depascale1; Giacomo Emmi10; Pasquale Esposito11, 12; Paride Fenaroli13; Cinzia Ferio14; Franco Franceschini15; Micaela Fredi 16; Giuliana Marongiu4; Giovanni Orsolini17; Giulia Pazzola18; Daniela Picciotto19; Luca Quartuccio20; Francesca Ruzzon 21; Domenico Santoro22; Ettore Silvagni6, 23; Paola Tomietto24; Francesca Romana Spinelli25; Luca Moroni26; Francesca Brunini27; Matteo Piga28; Valentina Binda29; Carmelita Marcantoni30; Angelo Ferrantelli31; SILVIA DI MICELI31; Filippo Vesentini1; Margherita Zen1; Roberta Ramonda1; Andrea Doria1; Gabriella Moroni2, 3; Luca Iaccarino1
|